BTAX / Biostax Corp. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 BIOSTAX CORP (Exact na

OMB APPROVAL

Form 25 OMB APPROVAL OMB Number: 3235-0080 Expires: May 31, 2027 Estimated average burden hours per response: 1.

Exhibit 99.2 - Press Release

Press Release Exhibit 99.2 - Press Release Biostax Corp Announces Intention to file a Form 25 For Voluntary OTC-Pink Delisting And SEC Deregistration For Immediate Release* Orlando Florida – October 6, 2024 ** - Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company") today announced its intention to voluntarily delist its common stock from the OTC Pink marketplace. This decision comes as part o

Joint Written Consent of Majority of Shareholders of Biostax Corp (a Florida corporation) in Lieu of Special Meeting

PDF to EDGAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Biostax Corp. Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2431 Aloma Ave.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 BIOSTAX CORP (Exact name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment no. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment no. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 BIOSTA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25

NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 000-54933 CUSIP Number 45252A107 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54933 BIOSTAX CORP

List of Subsidiaries of the registrant

Exhibit 21.1 List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (“SME”) to be able to use administrative and financial assistance programs offered by the European Me

Code of Business Ethics and Conduct

Exhibit 14.1

First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022.

Exhibit 10.6

Settlement Agreement between Immune Therapeutics, Inc. and Jack Brewer dated October 23, 2022.

Exhibit 10.7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 BIOSTAX CORP (Exact name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 000-54933 CUSIP Number 45252A107 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

List of Subsidiaries of the registrant

Exhibit 21.1 List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (“SME”) to be able to use administrative and financial assistance programs offered by the European Me

Code of Business Ethics and Conduct

Exhibit 14.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54933 BIOSTAX CORP (Exact

First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022.

Exhibit 10.6

Settlement Agreement between Immune Therapeutics, Inc. and Jack Brewer dated October 23, 2022.

Exhibit 10.7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 000-54933 CUSIP Number 45252A305 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 BIOSTAX CORP (Exact na

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BIOSTAX CORP (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorpor

xhibit 99.1

Exhibit 99.1 Biostax Announces a Director Appointment of Influential Business Leader Craig Suro Orlando, FL, November 15, 2023 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Influential Business Leader Roger “Craig” Suro. Renowned Virginia native, Mr. Suro, has emerged as a driving force in the realms of busine

Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors

Exhibit 99.1 Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors Orlando, FL, November. 2, 2023 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC, boasting a ric

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 BIOSTAX CORP (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorpor

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 Biostax Corp. (Exact name of registrant as specified in charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission File Number) (

Amended and Restated By-laws of Biostax Corp.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF Biostax Corp. a Florida Corporation Revised and Adopted on October 21, 2023 ARTICLE I Shareholders Section 1. Annual Meetings. An annual meeting of shareholders shall be held for the election of directors on such date, and at such time and place as the Board of Directors may, from time to time, determine. Any other proper business may be transacted at an

Articles of Amendment to the Articles of Incorporation

Exhibit 3.1 Articles of Amendment to Articles of Incorporation of IMMUNE THERAPEUTICS, INC. (Name of Corporation as currently filed with the Florida Dept. of State) P93000082736 (Document Number of Corporation (if known) Pursuant to the provisions of section 607.1006, Florida Statutes, this Florida Profit Corporation adopts the following amendment(s) to its Articles of Incorporation: A. If amendin

Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment

Exhibit 99.1 Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment Orlando, FL, OCT. 24, 2023 (GLOBE NEWSWIRE)– Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative rebranding initiative. Both the State of

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 (September 14, 2023) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of i

Biostax Corp Announces the Passing of Esteemed Director, Henry Louis Salomonsky

Exhibit 99.1 Biostax Corp Announces the Passing of Esteemed Director, Henry Louis Salomonsky [Orlando, FL] Sept. 14, 2023 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax” or “the Company”) sadly announces the passing of Henry Louis Salomonksy, a dedicated member of its Board of Directors. Mr. Salomonksy passed away on August 31, 2023, surrounded by famil

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 (July 25, 2023) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorp

Executive Consulting Agreement, dated July 25, 2023, between Immune Therapeutics, Inc. and Noreen Griffin

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 000-54933 CUSIP Number 45252A107 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, INC.

Amendment No. 1 to Executive Consulting Agreement between the Company and Kelly O. Wilson dated April 12, 2023

Exhibit 10.1

Amendment No. 3 to License Agreement between the Company and Statera Biopharma, Inc. dated April 15, 2023

Exhibit 10.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 12, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 12, 2023) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorpora

The settlement between Statera Biopharma, Inc. and Biostax Corp. include an amended royalty-bearing license agreement and a joint petition to dismiss the involuntary bankruptcy case against Statera Biopharma, Inc.

Exhibit 99.1 Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies. The settlement between Statera Biopharma, Inc. and Biostax Corp. include an amended royalty-bearing license agreement and a joint petition to dismiss the involuntary bankruptcy case against Statera B

Settlement Agreement between the Company and Statera Biopharma, Inc. dated April 12, 2023

Exhibit 10.2

Settlement Agreement between Immune Therapeutics, Inc. and Jack Brewer dated October 23, 2022.

Exhibit 10.7

List of Subsidiaries of the registrant

Exhibit 21.1 List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (“SME”) to be able to use administrative and financial assistance programs offered by the European Me

First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022.

Exhibit 10.6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54933 IMMUNE THERAPEUTICS,

Code of Business Ethics and Conduct

Exhibit 14.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25

NT 10-K 1 formnt-10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 000-54933 CUSIP Number 45252A107 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement IMMUNE THERAPEUTICS, INC. (Name of R

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 (February 28, 2023) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement IMMUNE THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement IMMUNE THERAPEUTIC

Resignation Letter of Dr. Roscoe Moore, dated December 17, 2022

Exhibit 17.2 Roscoe Moore DVM, MPH, PhD, 14315 Artic Ave, Rockville, MD 20853-2253 (301) 8711134 [email protected] December 17, 2022 Ms. Kelly Wilson President and CEO Immune Therapeutics, Inc. 2431 Aloma Avenue #124 Winter Park, Florida 32792 Dear Ms. Wilson: Please accept this letter as formal notification of my intent to resign from my position as a member of the Board of Directors of Immun

Resignation Letter of Mr. Kevin Phelps, dated December 15, 2022

Exhibit 17.1 Kevin J. Phelps 14 Oakfield Way Pittsford, New York 14534 585-820-5474 December 15, 2022 Ms. Kelly Wilson President and CEO Immune Therapeutics, Inc. 2431 Aloma Avenue #124 Winter Park, Florida 32792 Dear Ms. Wilson: Please accept this letter as formal notification of my intent to resign from my position as a member of the Board of Directors of Immune Therapeutics, Inc. (the ?Company?

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 (December 31, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

PRE 14C 1 ea170356-pre14cimmunetherap.htm PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)

IMUN / Immune Therapeutics, Inc. / Salomonsky Henry Louis - SCHEDULE 13D Activist Investment

SC 13D 1 ea170272-13dsalomimmune.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 IMMUNE THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45252A107 (CUSIP Number) Henry Louis Salomonsky c/o Immune Therapeutics, Inc. 2431 Aloma Ave., Suite 124 Winter Park, FL 32792 888-613-8

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Immune Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, I

Resignation Letter of Dr. Stephen Wilson, dated November 3, 2022

Exhibit 17.1 Stephen S. Wilson 5229 Brickfield Lane San Diego, CA 92130 [email protected] NOTICE OF RESIGNATION November 1, 2022 Immune Therapeutics, Inc. 2431 ALOMA AVE #124 WINTER PARK FL. 32792 Dear Chairman Selsky, and Directors of IMUN, As of this writing, November 1, 2022, I?m resigning from my position as President/CEO and Director of the Company. I have worked diligently to assist the Compa

Executive Consulting Agreement between Immune Therapeutics, Inc. and Kelly Wilson, dated November 1, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 9, 2022).

Exhibit 10.1 EXECUTIVE CONSULTING AGREEMENT IMMUNE THERAPEUTICS, INC. AND KELLY WILSON November 1, 2022 This Executive Consulting Agreement (this ?Agreement?) is made and entered into as of November 1, 2022 by and between Ms. Kelly O. Wilson (?Executive?), and Immune Therapeutics, Inc. a Florida corporation (the ?Company??), who are hereinafter sometimes collectively referred to as ?the parties.?

Resignation Letter of Dr. Clifford Selsky, dated November 4, 2022

Exhibit 17.2 November 4, 2022 Dear BOD of Immune I am tending my resignation effective immediately from the BOD. My practice has become increasingly busy and I have no time to continue to serve. I wish you all well. Regards, /s/ Dr. Cliff Selsky Dr.Cliff Selsky

Executive Consulting Agreement between Immune Therapeutics, Inc. and Glen Farmer, dated November 1, 2022 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on November 9, 2022).

Exhibit 10.2 EXECUTIVE CONSULTING AGREEMENT IMMUNE THERAPETICS, INC. AND GLEN FARMER November 1, 2022 This Executive Consulting Agreement (this ?Agreement?) is made and entered into as of November 1, 2022 by and between Mr. Glen Farmer (?Executive?), and Immune Therapeutics, Inc. a Florida corporation (the ?Company??), who are hereinafter sometimes collectively referred to as ?the parties.? WITNES

Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development

Exhibit 99.1 Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development Orlando, FL, November 9, 2022 (GLOBAL NEWSWIRE) ? Immune Therapeutics, Inc. (OTC PINK:IMUN) (?Immune? or ?IMUN?) today announced that its Chief Executive Officer, President, and director, Stephen Wilson, PhD, resign

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 (November 9, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incor

Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd. (incorporated by reference to Form 8-K filed on October 12, 2022).***

Exhibit 10.1 DEFINITIVE AGREEMENT INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT (the ?Agreement?), effective September 30, 2022 (the ?Effective Date?), is entered into by Immune Therapeutics, Inc., a corporation duly organized and existing under the laws of the state of Florida, having a principal place of business at 2431 Aloma Ave, Winter Park, Florida (her

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 (September 30, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of inc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 (September 20, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of i

Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors

Exhibit 99.1 Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors ORLANDO, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) ? Immune Therapeutics, Inc. (OTC PINK:IMUN) (?Immune? or ?IMUN?), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products with a well-defined path to market, today announced the a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NT 10-Q 1 formnt10-q.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ............ 2.50 FORM 12b-25 SEC File Number: 000-54933 NOTIFICATION OF LATE FILING CUSIP Number: 45252A 107 (Check one) [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] F

Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer

Exhibit 99.1 Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer ORLANDO, FL, August 4, 2022 (GLOBE NEWSWIRE) ? Immune Therapeutics, Inc. (OTC PINK:IMUN) (?Immune? or ?IMUN?), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 (August 2, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorpora

Convertible Promissory Note in the Principal Amount of $200,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps

Exhibit 4.3 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH

Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps

Exhibit 4.2 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH

Separation and Release Agreement, dated July 19, 2022, between Kevin Phelps and Immune Therapeutics, Inc.

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the ?Separation Agreement?) is made and entered into as of the Effective Date (as that term is defined in Section 29 below) by and between Kevin Phelps (the ?Executive? or ?Phelps?) and Immune Therapeutics, Inc., a Florida corporation (the ?Company? or ?ITI?). The Executive and the Company are

Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

Exhibit 99.1 Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer ORLANDO, Fl., July 22, 2022 (Globe Newswire) - Immune Therapeutics, Inc. (OTC Pink: IMUN) (?Immune? or ?IMUN?), a specialty pharmaceutical company involved in the acquisition, development and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 (July 18, 2022) IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporati

Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps

Exhibit 4.1 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 6, 2022 (June 29, 2022) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporatio

Term Sheet

Exhibit 10.1

ORLANDO, Fla. — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through t

Exhibit 99.1 ORLANDO, Fla. ? Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body?s immune system, today announced that it will expand its Board of Directors from two to five mem

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2022 (May 31, 2022) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, INC.

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (?SME?) to be able to use administrative and financial assistance programs offered by the European Me

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation.

Exhibit 10.61

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation.

EX-10.65 5 ex10-65.htm Exhibit 10.65

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey.

EX-10.64 4 ex10-64.htm Exhibit 10.64

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation.

Exhibit 10.62

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey.

Exhibit 10.66

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT UNDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 000-54933 IMMUNE THERAPEUTICS, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, INC. (

Articles of Amendment to Articles of Incorporation, filed October 27, 2014, incorporated by reference to Exhibit 3.2 Immune Therapeutics, Inc. 10-Q Quarterly Report filed with the Securities and Exchange Commission on August 16, 2021.

Exhibit 3.2

Amendment No. 1 to the Agreement and Representation Letter between Cytocom Inc. and Immune Therapeutics, Inc., entered into with an effective date of August 12, 2020 incorporated by reference to Exhibit 10.2 of Immune Therapeutics, Inc. Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 16, 2021.

Exhibit 10.2

IMUN / Immune Therapeutics, Inc. / Griffin Noreen - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Immune Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45252A107 (CUSIP Number) Noreen Griffin 100 S Eola Dr Unit 1703 Orlando, FL 32801 (407) 375-5462 (Name, Address and Telephone Number of Person Authorized to Receive No

Letter of Intent, dated May 25, 2021, incorporated by reference to Exhibit 10.1 of Immune Therapeutics, Inc. Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 2, 2021.

Ex 10.1 TERM SHEET Proposed Terms of Transaction This term sheet (?Term Sheet?) sets forth certain material terms for the contribution of Lenders and Immune Therapeutics Inc (?IMUN?) (collectively, the ?Transaction?). Subject to the foregoing, the parties propose to negotiate in good faith to agree upon the terms of any required agreements for the Transaction that will provide for and/or incorpora

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2021 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

Immune Therapeutics announces financing and debt restructuring plan.

Ex. 99.1 Immune Therapeutics announces financing and debt restructuring plan. Orlando, Florida June 2, 2021, Immune Therapeutics Inc. (OTC-PINK: IMUND) (the “Company”) announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt. The Company received the t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, I

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey.

Exhibit 10.68

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation.

Exhibit 10.67

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey.

Exhibit 10.70

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation.

Exhibit 10.66

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation.

EX-10.69 5 ex10-69.htm Exhibit 10.69

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ............ 2.50 FORM 12b-25 SEC File Number: 000-54933 NOTIFICATION OF LATE FILING CUSIP Number: 45252A 107 (Check one) [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39.

Exhibit 10.59

Annual Report -

10-K 1 form10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 000-54933 IMMUNE T

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (?SME?) to be able to use administrative and financial assistance programs offered by the European Me

-

NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ............ 2.50 SEC File Number: 000-54933 CUSIP Number: 45252A 107 (Check one) [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] F

Current Report

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 21, 2021 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorpo

Agreement dated August 12, 2020 between Immune Therapeutics, Inc. and Cytocom, Inc. assigning all of .Immune Therapeutics’ right, title and interest in LDN and MENK in Developing Markets and the License to those products to Cytocom, and related matters.

Exhibit 10.73

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTIC

Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs

Exhibit 99.1 Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions WINTER PARK, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) — Cytocom, Inc. (Cytocom), a lea

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 20, 2020 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commissio

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54933 I

-

August 28, 2020 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ameen Hamady Re: Immune Therapeutics, Inc. Form 10-K for the year ended December 31, 2019 Filed on May 14, 2020 File No. 000-54933 Dear Mr. Hamady: Set forth below are the responses of Immune Therapeutics, Inc. (the “Company”) to the comments of the staff of

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54933 I

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2020 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Amendment to the Articles of Incorporation filed February 5, 2020 approving a reverse split of issued and outstanding shares of common stock by 1,000 to 1.

Exhibit 10.71

Amendment to the Articles of Incorporation filed March 12, 2020 approving an increase in authorized shares of common stock from 500,000,000 to 750,000,000.

Exhibit 10.72

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, IN

Board Resolution dated July 24, 2020

Ex No. 10.2 WRITTEN CONSENT OF THE BOARD OF DIRECTORS OF IMMUNE THERAPEUTICS, INC. The undersigned, being all of the Directors (the “Directors”) of Immune Therapeutics, Inc., a Florida corporation (the “Company”), required to enact these resolutions by majority, pursuant to Section 607.0821 of the Florida Business Corporation Act and the Bylaws of the Company, hereby consent to the following actio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2020 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission F

Employment Agreement with Kevin Phelps effective as of April 29, 2020 (filed as Exhibit 10.1 to our Current Report on Form 8-K on July 27, 2020, and incorporated herein by reference.).

Ex. No. 10.1 Immune Therapeutics, Inc. Short-Form Employment Agreement This Employment Agreement (this “Agreement”) is made effective as of April 29, 2020, by and between Immune Therapeutics, Inc. (“Immune”), a Florida Corporation, and Kevin J. Phelps (“Executive”), of Rochester, New York. A. Immune is engaged in the business of biotechnology development and intends to commence addition discovery

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, I

Securities Purchase Agreement dated as of June 15, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of $38,000

Exhibit 10.67 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 15, 2020, by and between IMMUNE THERAPEUTICS, INC., a Florida corporation, with its address at 2431 Aloma Ave #124, Winter Park, FL 32792 (the “Company”), and GENEVA ROTH REMARK HOLDINGS, INC., a New York corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY

Articles of Amendment to Articles of Incorporation for Immune Therapeutics, Inc. filed on March 12, 2020 (incorporated by reference to Exhibit 10.69 to the Quarterly Report on Form 10-Q filed on June 29, 2020).

Exhibit 10.69

Securities Purchase Agreement dated as of May 4, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of $53,000

Exhibit 10.66 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 4, 2020, by and between IMMUNE THERAPEUTICS, INC., a Florida corporation, with its address at 2431 Aloma Ave #124, Winter Park, FL 32792 (the “Company”), and GENEVA ROTH REMARK HOLDINGS, INC., a New York corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11

Articles of Amendment to Articles of Incorporation, incorporated by reference to Exhibit 10.68 of Immune Therapeutics, Inc. Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on June 29, 2020

Exhibit 10.68 CORPORATE RESOLUTION OF THE BOARD OF DIRECTORS OF IMMUNE THERAPEUTICS, INC. The undersigned, constituting all of the Directors of Immune Therapeutics. Inc. (the “Corporation”), a Florida C-Corporation, do hereby consent to the adoption of, and hereby approve and adopt, the following resolutions effective as of 02 February 2020. WHEREAS, the Board of Directors of’ the Corporation deem

IMUN / Immune Therapeutics, Inc. / Ahmetaj Erjon - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 01 Immune Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 45252A107 (CUSIP Number) Calendar Year 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

IMUN / Immune Therapeutics, Inc. / Iliad Research & Trading, L.P. - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immune Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45252A107 (CUSIP Number) Calendar Year 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

License Agreement dated January 15, 2020 with Forte Biotechnology Int’l. Corp. ∞

Exhibit 10.62 IMMUNE THERAPEUTICS & FORTE BIOTECHNOLOGY INTL CORP LICENSE AGREEMENT 15 January 2020 SUMMARY OF TERMS Agreement: Immune Therapeutics, Inc. (“Immune” or “IMUN” or “Licensor”) owns or otherwise controls intellectual property relating to the proprietary therapeutic composition known as “Low Dose Naltrexone” or “Lodonal” or “LDN” and also owns or otherwise controls to the composition kn

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 000-54933 IMMUNE THERAPEUTICS, INC. (E

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2020 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

Second Amendment to License Agreement with Cytocom Inc., effective December 31, 2018 and signed April 8, 2019.∞

EX-10.60 3 ex10-60.htm Exhibit 10.60 AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENT This amendment (“Third Amendment”) to the Second Amendment to The License Agreement is effective December 31, 2018 (“Effective Date”) by and between Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave, Wint

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39.∞

Exhibit 10.59 PROMISSORY NOTE $231,478.39 February 27, 2019 RECITALS WHEREAS Immune Therapeutics, Inc (the “COMPANY” entered into an agreement with the Phoenix Group (“TPG”) on November 21, 2016. WHEREAS TPG has accrued monthly payments of $37,000 (thirty-seven thousand dollars) for the services of Mr. Rudy Williams and Dr. Vincent Ahonkhai for the months of January 2018 through June of 2018 total

Convertible Promissory Note dated March 30, 2020 to Redstart Holdings Corp. in the principal amount of $53,000. ∞

Exhibit 10.64 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE

PRC Amendment to The Second Amendment to the License Agreement effective December 31, 2018 with Cytocom, Inc. and signed May 12, 2020. ∞

Exhibit 10.65 PRC AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENT This amendment to the Second Amendment to The License Agreement (herein referred to as the “PRC Amendment”) is effective December 31, 2018 (“Effective Date”) by and between Cytocom, Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 29, 2020 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorpora

Immune Therapeutics, Inc. Focusing to Drive Shareholder Value

Ex. 99.1 Immune Therapeutics, Inc. Focusing to Drive Shareholder Value Winter Park, FL, May 5, 2020 — OTC PR WIRE –Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive sh

Mutual Release and Non-Disparagement Agreement effective April 30, 2020

Exhibit 10.1 MUTUAL RELEASE AND NON-DISPARAGEMENT AGREEMENT [Immune Therapeutics, Inc. and Mr. Michael K. Handley] This Mutual Release and Non-Disparagement Agreement (the “Agreement”) is entered into on April 26, 2020, by and between Michael K. Handley (“Mr. Handley”), a resident of the State of Colorado, and Immune Therapeutics, Inc. (the “Company”), a Florida Corporation. PURPOSE The mutual rel

Board Resolution dated April 30, 2020

Exhibit 10.2 WRITTEN CONSENT OF THE BOARD OF DIRECTORS OF IMMUNE THERAPEUTICS, INC. The undersigned, being all of the Directors (the “Directors”) of Immune Therapeutics, Inc., a Florida corporation (the “Company”), required to enact these resolutions by majority, pursuant to Section 607.0821 of the Florida Business Corporation Act and the Bylaws of the Company, hereby consent to the following acti

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Immune Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Florida 000-54933 59-3226705 (State or other jurisdiction of Incorporation) (Commi

SEC Extension application

Exhibit 3.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report

Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications

EX-99.1 3 ex99-1.htm Exhibit 99.1 Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=

IMUN / Immune Therapeutics, Inc. NT 10-K - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q

Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19

Exhibit 99.1 Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19 By Corporate News, News, Press Releases Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Drug Development Programs Also Moving Forward ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc.

Letter of Intent dated March 17, 2020 with Cytocom, Inc., setting forth the preliminary terms and conditions of a potential collaboration agreement for the development of Lodonal™ and IRT-101 for use against COVID-19 (Filed as Exhibit 10.1 to our Current Report on Form 8-K on March 20, 2020, and incorporated herein by reference.).

EX-10.1 2 ex10-1.htm Exhibit 10.1 17 March 2020 Ms. Noreen Griffin President & Chief Executive Officer Cytocom, Inc. 3001 Aloma Ave., Winter Park, FL 32792 SUBJECT: BINDING LETTER OF INTENT Dear Ms. Noreen Griffin: Immune Therapeutics Inc. (“IMUN”) and Cytocom, Inc. (“CYTO”) have been discussing a possible collaboration between the two companies to create a program to develop Lodonal™ (IRT-103) an

Current Report

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 Immune Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Florida 000-54933 59-3226705 (State or other jurisdiction of Incorp

Board Resolution

Exhibit 10.1 CORPORATE RESOLUTION OF THE BOARD OF DIRECTORS OF IMMUNE THERAPEUTICS, INC. The undersigned, constituting all of the Directors of Immune Therapeutics, Inc. (the “Corporation”), a Florida C-Corporation, do hereby consent to the adoption of, and hereby approve and adopt, the following resolutions effective as of 12 February 2020. WHEREAS, On September 24, 2019 Jack Brewer resigned from

Immune Therapeutics, Inc. Appoints New Independent Director

EX-99.1 3 ex99-1.htm Exhibit 99.1 Immune Therapeutics, Inc. Appoints New Independent Director Fort Collins Co., February 18, 2020 — OTC PR WIRE –Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced the appointment

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2020 Immune Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Florida 000-54933 59-3226705 (State or other jurisdiction of Incorporation) (Commi

IMUN / Immune Therapeutics, Inc. / Ahmetaj Erjon - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Immune Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 45252A107 (CUSIP Number) November 19, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

IMUN / Immune Therapeutics, Inc. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTIC

IMUN / Immune Therapeutics, Inc. NT 10-Q - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: September 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 25, 2019 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commissio

IMUN / Immune Therapeutics, Inc. DEFR14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDED REVISED SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Employment Agreement with Michael Handley dated September 20, 2019 (Filed as Exhibit 10.1 to our Current Report on Form 8-K on September 25, 2019, and incorporated herein by reference.).

IMMUNE THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated September 2019 (the “Effective Date”), is by and between Immune Therapeutics, Inc., a Delaware C-corporation (the “Company”) and Michael K. Handley (the “Executive”). W I T N E S S E T H: WHEREAS, the Company desires to employ the Executive as its Chief Executive Officer & President, and th

Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2019 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incor

IMUN / Immune Therapeutics, Inc. DEFR14A - -

DEFR14A 1 defr14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 REVISED SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rul

IMUN / Immune Therapeutics, Inc. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number 000-54933 IMMUNE THERAPEUTICS, IN

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 30, 2019 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

IMUN / Immune Therapeutics, Inc. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (Exact

Second Amendment to License Agreement by and between: Cytocom Inc. and Immune Therapeutics Inc., signed April 8, 2019.

SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment to License Agreement (“Second Amendment”) is effective December 31, 2018 (“Effective Date”), by and between: Cytocom Inc.

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39.

PROMISSORY NOTE $231,478.39 February 27, 2019 RECITALS WHEREAS Immune Therapeutics, Inc (the “COMPANY” entered into an agreement with the Phoenix Group (“TPG”) on November 21, 2016. WHEREAS TPG has accrued monthly payments of $37,000 (thirty-seven thousand dollars) for the services of Mr. Rudy Williams and Dr. Vincent Ahonkhai for the months of January 2018 through June of 2018 totaling $222,000 (

IMUN / Immune Therapeutics, Inc. / Iliad Research & Trading, L.P. - NONE Passive Investment

SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Immune Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45252A107 (CUSIP Number) Calendar Year 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate

IMUN / Immune Therapeutics, Inc. NT 10-Q

NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: March 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transiti

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2019 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

Letter to Shareholders

Dear Shareholders, On behalf of Immune Therapeutics, Inc., we’d like to take the opportunity to address and explain the decisions behind the proposals in the definitive proxy statement filed on Schedule14A on April 30, 2019 (the “Proxy Statement”), about which some shareholders have inquired. The Proxy Statement sets forth certain proposals unanimously recommended by our board in order to help sim

IMUN / Immune Therapeutics, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39.

PROMISSORY NOTE $231,478.39 February 27, 2019 RECITALS WHEREAS Immune Therapeutics, Inc (the “COMPANY” entered into an agreement with the Phoenix Group (“TPG”) on November 21, 2016. WHEREAS TPG has accrued monthly payments of $37,000 (thirty-seven thousand dollars) for the services of Mr. Rudy Williams and Dr. Vincent Ahonkhai for the months of January 2018 through June of 2018 totaling $222,000 (

IMUN / Immune Therapeutics, Inc. (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 000-54933 IMMUNE THERAPEUTICS, INC. (E

List of Subsidiaries µ

Exhibit 21. List of Subsidiaries TNI BioTech International, Ltd., Tortola, British Virgin Islands. Incorporated in October 2012. Set up to market and sell Naltrexone outside the U.S. TNI BioTech, LTD, United Kingdom. Incorporated in August 2013. Set up as a micro, small or medium-sized enterprise (“SME”) to be able to use administrative and financial assistance programs offered by the European Med

IMUN / Immune Therapeutics, Inc.

NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Trans

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 2, 2019 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

IMUN / Immune Therapeutics, Inc. PRER14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

IMUN / Immune Therapeutics, Inc. CORRESP - -

December 21, 2018 Jeffrey Gabor United States Securities and Exchange Commission Washington, D.

IMUN / Immune Therapeutics, Inc. PRER14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

IMUN / Immune Therapeutics, Inc. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

IMUN / Immune Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (E

IMUN / Immune Therapeutics, Inc. S-8

S-8 1 forms-8.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Florida 59-3226705 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 37 North Orange Ave, Suite 607 Orlando, FL 32801

IMUN / Immune Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (Exact

Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 4, 2018 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States

(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States ORLANDO, Fla.

Amended and restated License Agreement with Cytocom, Inc. dated May 1, 2018 (filed as Exhibit 10.1 to our Current Report dated June 4, 2018, and incorporated herein by reference).

Execution Copy LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is made as of May 1, 2018 (the “Effective Date”) by and between Cytocom Inc.

Stock Purchase Agreement with Cytocom, Inc. dated June 4, 2018 (filed as Exhibit 10.2 to our Report on Form 8-K dated June 4, 2018, and incorporated herein by reference).

STOCK PURCHASE AGREEMENT This STOCK Purchase Agreement (this “Agreement”) is made and entered into effective as of the 4th day of June 2018, by and between Immune Therapeutics, Inc.

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2018 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Loan agreement and promissory note with Joel Yanowitz, dated January 9, 2018, for $50,000 (filed as Exhibit 10.23 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference).

EX-10.23 2 ex10-23.htm LOAN AGREEMENT This LOAN AGREEMENT (this “Agreement”), dated January 9, 2018 (the “Effective Date”), is entered into by and between Immune Therapeutics, Inc., a Florida corporation (“Borrower”), and Joel Yanowitz (‘‘Lender”). RECITALS WHEREAS, Borrower has requested that Lender provide Borrower with a term loan bearing interest at a fixed rate as more particularly described

IMUN / Immune Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (Exact

Loan agreement and promissory note with Rogoff Family Trust, dated February 13, 2018, for $50,000 (filed as Exhibit 10.24 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference).

LOAN AGREEMENT This LOAN AGREEMENT (this “Agreement”), dated February 13, 2018 (the “Effective Date”), is entered into by and between Immune Therapeutics, Inc.

IMUN / Immune Therapeutics, Inc. / Iliad Research & Trading, L.P. - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Immune Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45252A107 (CUSIP Number) May 15, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment o

Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic Press Release | 04/26/2018 ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) - via OTC PR WIRE- Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infl

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 26, 2018 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Promissory Note dated April 5, 2017 to Robert J. Dailey in the principal amount of $150,000.

Intellectual Property Assignment Agreement with Cytocom, Inc. dated September 4, 2015. µ

Securities Purchase Agreement and related agreements with JMJ Financial dated April 12, 2016 (filed as Exhibit 10.1 to our Current Report 8-K on April 18, 2016, and incorporated herein by reference).

Consulting Agreement with Joyce Banda dated September 1, 2016. µ

Securities Purchase Agreement and Warrant dated May 1, 2017 with Ira Gaines. µ

Services Agreement, dated December 15, 2014, between Immune Therapeutics, Inc. and Aronstam Management Services, Inc. µ

Real Property Leases for Florida Office and Extensions dated July 19, 2017 and November 13, 2017

Settlement and mutual release agreement dated October 12, 2017 with Phoenix Fund Management, LLC and Far East Holdings, LLC. µ

Patent License Agreement dated September 24, 2014 between Dr. Jill P. Smith, LDN Research Group LLC and Cytocom, Inc. and related agreements. µ

Extension of Employment Agreement with Noreen Griffin dated March 9, 2018. µ

Consulting Master Services Agreement with Coté Orphan, LLC dated February 16, 2016. µ

Independent Corporate Development and Legal Advising Agreement with CSJ and August Strategic & Legal Advisors, Inc. dated December 6, 2017 µ

Distribution Agreement with TNI BioTech International Ltd. and Omaera Pharmaceuticals Ltd. Dated August 22, 2017.

Extension of AHAR Agreement dated March 29, 2016. µ

Promissory Note Settlement Agreement, dated September 26, 2014, between Immune Therapeutics, Inc. and Robert Dailey for notes equaling $400,000 µ

IMUN / Immune Therapeutics, Inc. 10-K (Annual Report)

10-K 1 form10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 001-34918 IMMUNE T

Promissory Note Settlement Agreement, dated September 26, 2014, between Immune Therapeutics, Inc. and Robert Dailey for notes equaling $399,000 µ

Settlement agreement with Phoenix Fund Management, LLC dated February 28, 2017. µ

Iliad Research and Trading (i) promissory note and (ii) warrant dated October 25, 2017. µ

Independent Corporate Development and Consulting Agreement with CSJ Group, LLC, and Advanced BioStrategies, Inc. dated December 5, 2017. µ

Extension of Employment Agreement with Peter Aronstam dated July 1, 2017. µ

EX-10.37 8 ex10-37.htm

Securities Purchase Agreement dated October 25, 2017 with Iliad Research and Trading, L.P. µ

EX-10.52 21 ex10-52.htm

Settlement agreement with Mr. Marshall Faulk dated April 3, 2017. µ

Promissory Note dated February 6, 2017 issued to Phoenix Fund Management, LLC.

Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease

Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease Press Release | 03/26/2018 ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE— Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lo

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2018 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commissio

Immune Therapeutics, Inc. Shareholder Update Letter

Immune Therapeutics, Inc. Shareholder Update Letter PR Newswire ORLANDO, Fla., Nov. 30, 2017 ORLANDO, Fla., Nov. 30, 2017 /PRNewswire/ ? Immune Therapeutics, Inc. (OTCQB: IMUN), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products to alleviate human suffering in HIV/AIDS, cancer, pain, opportunistic infections and autoi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commissi

Settlement and Mutual Release Agreement with Phoenix Fund Management, LLC dated October 12, 2017.

IMUN / Immune Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (E

Securities Purchase Agreement and Note with Iliad Research & Trading LP dated October 20, 2017.

Distribution Agreement with Omaera Pharmaceuticals Ltd. dated August 22, 2017.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 12, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction (Commission (IRS Employer of

IMMUNE THERAPEUTICS, INC. ANNOUNCES exclusive agreement for sale of lodonal in kenya valued at over $31 million Agreement Illustrates Immune Therapeutics’ Commitment to Providing an Effective and Affordable Non-Toxic Treatment for HIV/AIDS Patients

- - PRESS RELEASE - - Investor/Media Contact: Bill Miller Investor Relations Partners Phone: 844-565-5665 bmiller@irpartnersinc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 24, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.

EX-99.1 2 ex99-1.htm Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc. Aug 23, 2017 OTC Disclosure & News Service - ORLANDO, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) today announced that it has appointed John H. Abeles, M.D. as Chairman and CEO of

IMUN / Immune Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (Exact

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

EX-99.1

IMMUNE THERAPEUTICS ANNOUNCES NAFDAC APPROVAL FOR MARKETING AND DISTRIBUTION OF LODONAL™ FOR THE TREATMENT OF HIV IN NIGERIA Immune Therapeutics Emerges as a Key Player in Immunotherapy Field

- - PRESS RELEASE - - Investor/Media Contact: Bill Miller Investor Relations Partners Phone: 844-565-5665 bmiller@irpartnersinc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 [ ] TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to Commission File Number IMMUNE THERAPEUTICS, INC. (Exact

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

IMMUNE THERAPEUTICS, INC. FILES LODONAL NEW DRUG APPLICATION IN KENYA

- - PRESS RELEASE - - Investor/Media Contact: Bill Miller Investor Relations Partners Phone: 844-565-5665 bmiller@irpartnersinc.

IMMUNE THERAPEUTICS, INC. STRENGTHENS BALANCE SHEET WITH DEBT SETTLEMENT

- - PRESS RELEASE - - Investor/Media Contact: Brandon Thompson Investor Relations Partners Phone: 844-565-5665 bthompson@irpartnersinc.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 4, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE For the Transition Period From to Commission File Number: 001-34918 IMMUNE THERAPEUTICS, INC. (E

IMMUNE THERAPEUTICS CLEARS CRITICAL REGULATORY HURDLE FOR LODONAL IN KENYA

- - PRESS RELEASE - - Investor/Media Contact: Brandon Thompson Investor Relations Partners Phone: 844-565-5665 bthompson@irpartnersinc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commission

IMMUNE THERAPEUTICS, INC. FURTHER STRENGTHENS BALANCE SHEET AS IT PREPARES FOR COMMERCIALIZATION

- - PRESS RELEASE - - Investor/Media Contact: Brandon Thompson Investor Relations Partners Phone: 844-565-5665 bthompson@irpartnersinc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A AMENDED CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation)

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2017 Date of Report (Date of earliest event reported) Immune Therapeutics, Inc. (Exact name of registrant as specified in its charter) Florida 000-54933 59-3226705 (State or other jurisdiction of incorporation) (Commissio

Immune Therapeutics, Inc. 4,015,621 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No.